Nuclear medicine is experiencing a renaissance, with U.S. Food and Drug Administration approval recently being obtained for theranostic agents and a wide variety of such agents soon to impact patient care significantly in the era of precision medicine. The NETTER-1 trial demonstrated the therapeutic effect of a theranostic agent in markedly improving progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Predominantly retrospective studies have demonstrated a significant response to 177Lu-labeled agents targeting prostate-specific membrane antigen (PSMA) in patients with prostate cancer. At least 2 prospective clinical trials involving 177Lu-PSMA agents are under way that will likely pave the way for Food and Drug Administration approval in the United States. A significant upside to theranostics is that patients tend to tolerate these agents better than chemotherapy. Theranostic compounds are likely to impact many cancers in the near future, not only through improvements in quality of life but also in terms of survival. This article provides an overview of already approved agents as well as those on the horizon. It is important that as these agents are clinically onboarded, nuclear medicine physicians have the expertise to deploy theranostics safely and efficiently, ensuring that these agents attain and maintain their position as leading lines of therapy in managing patients with cancer as well as becoming an important aspect of nuclear medicine practice in the future.

中文翻译：

---

Theranostics：利用分子成像和疗法来影响患者管理并确保核医学的未来。

核医学正在复兴，最近美国食品药品监督管理局（US Food and Drug Administration）批准了治疗诊断剂，并且各种各样的此类试剂很快将在精密医学时代显着影响患者护理。NETTER-1试验证明，治疗性药物可显着改善转移性胃肠胰腺神经内分泌肿瘤患者的无进展生存期。主要的回顾性研究表明，前列腺癌患者对177Lu标记的靶向前列腺特异性膜抗原（PSMA）的药物有明显反应。正在进行至少两项涉及177Lu-PSMA药物的前瞻性临床试验，这很可能为美国食品药品监督管理局的批准铺平道路。治疗学的一个重要方面是，与化疗相比，患者对这些药物的耐受性更高。治疗性化合物可能会在不久的将来影响许多癌症，不仅会改善生活质量，还会影响生存率。本文概述了已经批准的代理商以及即将推出的代理商。重要的是，随着这些药物在临床上的普及，核医学医师应具备安全有效地部署诊断学的专业知识，以确保这些药物获得并保持其在治疗癌症患者中的治疗领先地位，并成为重要方面未来的核医学实践。治疗性化合物可能会在不久的将来影响许多癌症，不仅会改善生活质量，还会影响生存率。本文概述了已经批准的代理商以及即将推出的代理商。重要的是，随着这些药物在临床上的普及，核医学医师应具备安全有效地部署诊断学的专业知识，以确保这些药物获得并保持其作为治疗癌症患者的治疗领先地位的地位，并成为重要的方面未来的核医学实践。治疗性化合物可能会在不久的将来影响许多癌症，不仅会改善生活质量，还会影响生存率。本文概述了已经批准的代理商以及即将推出的代理商。重要的是，随着这些药物在临床上的普及，核医学医师应具备安全有效地部署诊断学的专业知识，以确保这些药物获得并保持其在治疗癌症患者中的治疗领先地位，并成为重要方面未来的核医学实践。